Publication | Open Access

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group

Hematological MalignancyLymphoid NeoplasiaTarget-mediated EliminationMedicineMalignant Blood DisorderHematologyImmunologyPathologyImmune Checkpoint InhibitorAutoimmunityFilo GroupAdult T-cell Leukemia-lymphomaImmunotherapyOncologyCancer ResearchFcgr3a-158v/f Genotype